InsidersTradesSigma
Track the Medartis Holding AG stock price and the full directors' dealings record of the company, a listed equity based in Switzerland. Shares are quoted on the CH market, under the oversight of SIX SER. Operating in the Healthcare & Pharma sector, Medartis Holding AG has published 78 insider filings. Market capitalisation: €1.1bn. The latest transaction was reported on 31 August 2026 (Sale). Every trade is openly available.
78
Insider Decl.
n/a
Thresholds
€13m
43 ops.
Buy Volume
€24m
35 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Medartis Holding AG Strong Buy (bullish), based on 4 analysts. Average price target: CHF 108.75.
28Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,151 of 29,062 companies
41.5
score / 100
Value31
Quality52
FCF yld0.8%
Earn yld0.8%
EV/EBITDA27.7x
ROE5.7%
Gross mgn76%
Net mgn3.1%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations78 total
39 shares@ CHF 94.000.0003% mcap0.4% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8V000F3
1,344 shares@ CHF 92.020.011% mcap14.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8I00060
1,344 shares@ CHF 92.01760.011% mcap0.4% of flowISIN CH0386200239SIX:T1Q8I00060
372 shares@ CHF 67.150.0028% mcap3.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4T000D6
372 shares@ CHF 67.150.0028% mcap0.1% of flowISIN CH0386200239SIX:T1Q4T000D6
1,489 shares@ CHF 67.150.011% mcap14.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000K3
558 shares@ CHF 67.150.0042% mcap5.3% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000J5
1,489 shares@ CHF 67.150.011% mcap0.3% of flowISIN CH0386200239SIX:T1Q4R000K3
558 shares@ CHF 67.150.0042% mcap0.1% of flowISIN CH0386200239SIX:T1Q4R000J5
744 shares@ CHF 67.150.0056% mcap7.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O000I0
7,445 shares@ CHF 67.150.056% mcap70.2% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O000J8
7,445 shares@ CHF 67.150.056% mcap1.6% of flowISIN CH0386200239SIX:T1Q4O000J8
744 shares@ CHF 67.150.0056% mcap0.2% of flowISIN CH0386200239SIX:T1Q4O000I0
●
Anonymous (Executive member of the board of directors / member of senior management)
1,139 shares@ CHF 90.004.1% of flowISIN CH0386200239SIX:T1PCT00014
●
Anonymous (Executive member of the board of directors / member of senior management)
700 shares@ CHF 88.012.5% of flowISIN CH0386200239SIX:T1PCT00022
6,300 shares@ CHF 79.201.6% of flowISIN CH0386200239SIX:T1PCC000B8
18,939 shares@ CHF 79.204.8% of flowISIN CH0386200239SIX:T1PCC000D4
5,657 shares@ CHF 79.201.4% of flowISIN CH0386200239SIX:T1PCC000A0
8,333 shares@ CHF 79.202.1% of flowISIN CH0386200239SIX:T1PCC000P8
18,939 shares@ CHF 79.204.8% of flowISIN CH0386200239SIX:T1PCC000C6
6,313 shares@ CHF 79.201.6% of flowISIN CH0386200239SIX:T1PCC00085
17,576 shares@ CHF 79.204.5% of flowISIN CH0386200239SIX:T1PCC00093
126,276 shares@ CHF 79.2031.9% of flowISIN CH0386200239SIX:T1PCB000A1
715 shares@ CHF 88.00770.2% of flowISIN CH0386200239SIX:T1PC300058
1,441 shares@ CHF 85.16490.4% of flowISIN CH0386200239SIX:T1PBS00075
25 of 78 declarations
关于 Medartis Holding AG
Medartis Holding AG 是一家瑞士医疗器械公司，在瑞士 SIX 瑞士交易所 (SMI/SPI) 上市。公司成立于 1997 年，总部位于巴塞尔，已在骨科手术固定领域建立了专注的特许经营权，尤其在颅颌面 (CMF) 领域以及上肢和下肢解决方案方面实力雄厚。其根源与瑞士的精密制造传统息息相关，其商业模式围绕专有植入系统、以外科医生为中心的产品设计和强大的临床导向而形成。([stockanalysis.com](https://stockanalysis.com/quote/swx/MED/company/?utm_source=openai)) Medartis 开发、制造和销售用于稳定和修复骨折的植入解决方案。其产品组合包括用于创伤和重建手术的钢板、螺钉、器械和相关系统。该公司的差异化在于其骨科产品的广泛性、产品的技术质量以及其系统在手术室中的可用性。从投资者的角度来看，Medartis 将瑞士总部与国际商业足迹相结合，使其能够将“瑞士精度”与跨多个医疗保健市场的全球影响力相结合。([medartis.com](https://medartis.com/company/?utm_source=openai)) 竞争定位很重要。Medartis 在医疗技术市场的一个要求苛刻的细分市场中运营，大型全球医疗技术集团在此争夺医院准入、外科医生偏好和产品采用。在这种背景下，Medartis 作为一家专业公司而非广泛的骨科综合企业脱颖而出。这种更窄的焦点可能是一个优势：它支持技术深度、更紧密的客户关系和更有针对性的创新管道。这也意味着该公司的市场叙事通常以利基适应症的市场份额增长、产品发布和地域扩张为中心，而不仅仅是规模。([medartis.com](https://medartis.com/company/?utm_source=openai)) 最近的发展强化了这种增长态势。2026 年 3 月，Medartis 报告 2025 财年销售额为 269.3 亿瑞士法郎，并强调了运营盈利能力的改善，同时还描述了向更加分散、多品牌结构的组织转型。2026 年 4 月，股东在年度股东大会上强烈批准了董事会的提案。市场还关注了 2025 年末通过瑞士披露框架披露的管理层和董事会相关交易，这对于关注 SIX 监管报告和治理信号的投资者而言具有相关性。总而言之，Medartis 呈现为一家具有国际抱负的利基瑞士医疗技术公司，并得到运营势头和严谨战略重点的支持。([eqs-news.com](https://www.eqs-news.com/news/ad-hoc/medartis-builds-on-momentum-with-16-organic-sales-growth-and-core-ebitda-margin-exceeding-18/2065ea62-13b4-40e4-a62c-acc32c2b9cd3?utm_source=openai))
